Revisiting Expectations in an Era of Precision Oncology
Open Access
- 20 November 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 23 (3), 386-388
- https://doi.org/10.1634/theoncologist.2017-0269
Abstract
As we enter an era of precision medicine and targeted therapies in the treatment of metastatic cancer, we face new challenges for patients and providers alike as we establish clear guidelines, regulations, and strategies for implementation. At the crux of this challenge is the fact that patients with advanced cancer may have disproportionate expectations of personal benefit when participating in clinical trials designed to generate generalizable knowledge. Patient and physician goals of treatment may not align, and reconciliation of their disparate perceptions must be addressed. However, it is particularly challenging to manage a patient's expectations when the goal of precision medicine—personalized response—exacerbates our inability to predict outcomes for any individual patient. The precision medicine informed consent process must therefore directly address this issue. We are challenged to honestly, clearly, and compassionately engage a patient population in an informed consent process that is responsive to their vulnerability, as well as ever-evolving indications and evidence. This era requires a continual reassessment of expectations and goals from both sides of the bed.This publication has 18 references indexed in Scilit:
- Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment ResponseJAMA Oncology, 2015
- Research Participants' High Expectations of Benefit in Early-Phase Oncology Trials: Are We Asking the Right Question?Journal of Clinical Oncology, 2012
- Patients' Expectations about Effects of Chemotherapy for Advanced CancerThe New England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor TherapyJournal of Clinical Oncology, 2011
- The culture of faith and hopeCancer, 2010
- Distinguishing research from clinical care in cancer genetics: Theoretical justifications and practical strategiesSocial Science & Medicine (1982), 2009
- Clinical Trials and Medical Care: Defining the Therapeutic MisconceptionPLoS Medicine, 2007
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2The New England Journal of Medicine, 2001
- Sampling in qualitative research. Purposeful and theoretical sampling; merging or clear boundaries?Journal of Advanced Nursing, 1997